Speaker
Kenneth R. Chapman, MD, MSc, FRCPC, FACP, FCCP, FERS 
University of Toronto; Toronto, ON

Moderator
Erika Penz, MD, MSc, FRCPC
University of Saskatchewan, Saskatoon, SK

Session Description

In this presentation, we will examine the potential and actual impact of biological therapy in severe COPD patients. Insights are provided by studies with a range of biologics including anti-IL-5, IL-5r, IL-4r, TSLP and emerging non-Type 2 molecules.

Learning Objectives

At the end of this presentation, attendees will be able to:

  • Review the most current understanding of the heterogeneity of COPD, the spectrum of inflammatory pathways involved and the role of type 2 inflammation in COPD pathophysiology.
  • Review relevant data and provide rationale on existing treatment options for severe COPD patients from recent guidelines and pivotal studies with a focus on emerging biologic and targeted therapies.
  • Present the evolution of the clinical landscape, biologic therapies and propose what the futurestandard of care could be for patients based on the latest evidence.

CanMEDS Roles: Medical Expert, Communicator, Scholar

This session is co-developed by the CTS and Sanofi and is planned to achieve scientific integrity, objectivity and balance.